On May 30, Gelonghui | Pharmacomingjuno-B (02126.HK) announced the latest clinical data on patients with active systemic lupus erythematosus (“SLE”) in Chinese adults with active systemic lupus erythematosus (“SLE”) at the 2024 European Congress of Rheumatology (“EULAR 2024”).

According to disclosure, systemic lupus erythematosus is a chronic autoimmune disease that causes damage to multiple organs and tissues throughout the body. According to estimates, there are about 1 million people with systemic lupus erythematosus in China, ranking first in the world in total number and second in incidence. Currently, traditional treatments for systemic lupus erythematosus include corticosteroids, antimalarial drugs, non-steroidal anti-inflammatory drugs, cytotoxic drugs, and immunosuppression/modulators. However, traditional treatments affect treatment results due to poor long-term tolerability, which causes organ damage in patients due to poor disease control, which further affects prognosis and long-term survival. In particular, patients with moderate to severe active SLE requiring treatment with high doses of hormones and immunosuppressants.

Dr. Mark J. Gilbert, Chief Medical Officer of Pharmaceuticals Junuo, said, “Although new biologics and treatments for SLE have appeared one after another in recent years, there are still many SLE patients who have not responded to current treatments. Currently, there is no reliable treatment strategy to relieve or even cure the disease without medication. Short-term follow-up data from this study have initially shown that low doses of rekiolense injections have good safety in SLE patients and can bring deep relief, so that patients can achieve low disease activity or even no drug remission, and their application prospects in SLE treatment are worth looking forward to.”